Yedema C A, Kenemans P, Thomas C M, Massuger L F, Wobbes T, Verstraeten R, van Kamp G J, Hilgers J
Department of Obstetrics and Gynaecology, Free University Hospital, Amsterdam, The Netherlands.
Eur J Cancer. 1993;29A(7):966-71. doi: 10.1016/s0959-8049(05)80203-5.
In order to assess whether CA 125 serum levels reflect the outcome of cytoreductive surgery, CA 125 antigen levels were determined prior to and after debulking surgery in 50 ovarian cancer patients and compared to CA 125 serum levels before and after surgery in a control group of 140 patients undergoing laparotomy for various malignant or benign diseases. A significant CA 125 decrease in the first post-operative week was seen in 56% of ovarian cancer patients whereas 26% remained stable and 18% showed a significant increase after surgery. Although removal of tumour had been complete in all 14 stage I-II ovarian carcinomas, only 2 of these patients showed a subsequent significant CA 125 decrease after cytoreductive surgery, while 4 patients showed a significant increase. Such increases of CA 125 following surgery were also seen in uterine carcinomas (30%), in gastrointestinal carcinomas (75%) and in patients after laparotomy for benign gynaecological diseases (23%). CA 125 pre-treatment levels were significantly lower in patients with post-operative increases than in patients with stable or decreasing CA 125 patterns. Patients with stable CA 125 levels also had lower CA 125 pretreatment levels compared to patients with a post-operative CA 125 decrease. Post-operative increases were observed for at least 2 weeks after debulking in the case of ovarian cancer. Pre-operative levels of these patients were either within the normal range or moderately elevated. Serial measurements during surgery in partial debulking showed a rapid CA 125 decline within 24 h followed by increasing CA 125 values thereafter. Our data indicate that CA 125 serum levels in the direct post-operative period do not always reflect the outcome of cytoreductive surgery. There appears to be an effect on CA 125 levels caused by the abdominal surgical procedure itself. Consequently, CA 125 levels after abdominal surgery should be interpreted with caution.
为了评估CA 125血清水平是否反映肿瘤细胞减灭术的结果,对50例卵巢癌患者在肿瘤细胞减灭术前和术后测定了CA 125抗原水平,并与140例因各种恶性或良性疾病接受剖腹手术的对照组患者手术前后的CA 125血清水平进行了比较。56%的卵巢癌患者在术后第一周CA 125显著下降,而26%保持稳定,18%术后显著升高。尽管所有14例I-II期卵巢癌患者的肿瘤均已完全切除,但这些患者中只有2例在肿瘤细胞减灭术后CA 125随后显著下降,而4例患者显著升高。子宫癌(30%)、胃肠道癌(75%)以及接受良性妇科疾病剖腹手术的患者(23%)术后也出现了CA 125升高。术后CA 125升高的患者术前水平显著低于CA 125水平稳定或下降的患者。与术后CA 125下降的患者相比,CA 125水平稳定的患者术前CA 125水平也较低。卵巢癌患者在肿瘤细胞减灭术后至少2周内观察到术后CA 125升高。这些患者的术前水平要么在正常范围内,要么中度升高。部分肿瘤细胞减灭术手术过程中的连续测量显示,CA 125在24小时内迅速下降,随后CA 125值升高。我们的数据表明,术后直接阶段的CA 125血清水平并不总是反映肿瘤细胞减灭术的结果。腹部手术本身似乎对CA 125水平有影响。因此,腹部手术后的CA 125水平应谨慎解读。